There has been a steady rise in the demand for cell lines for the production of recombinant protein therapeutics as the US Food and Drug Administration (FDA) approves an increasing number of these biotherapeutics. While the period of 2006 to 2011 saw an average of 15 novel recombinant protein therapeutics gain approval, 2014 alone had 11 therapeutics gain FDA approval. The rising prevalence of communicable diseases, combined with increase in geriatric population, has driven the global biotherapeutics cell line development market. Moreover, strong initiatives taken by several governments to boost research and development in the field of life sciences have also contributed towards the growth of the biotherapeutics cell line development market.
Steady Growth in Store for Global Biotherapeutics Cell Line Development Market
According to a recent report by Transparency Market Research, the global market for biotherapeutics cell line development is forecast to expand at a steady CAGR of 7.50% from 2015 to 2022, growing from a value of US$56 mn in 2014 to US$99.8 mn in 2022. This growth can be attributed to a number of factors such as rise in vaccine production, development of innovative technologies boosting the scale of cell lines, the surging demand for monoclonal antibodies, and the increasing investments and funding from companies, governments, and research organizations. While the growing geriatric population, low income countries presenting lucrative opportunities, and the increasing risk of communicable diseases and pandemics is projected to fuel the biotherapeutics cell line development market in the coming years, the challenge of developing authentic and stable cell lines is sure to limit its growth.
Asia Pacific Presents Strong Opportunities for Growth
The global biotherapeutics cell line development market is geographically segmented into North America, Latin America, Asia Pacific, the Middle East and Africa, and Europe. North America dominates the worldwide market for biotherapeutics cell line development and this region is forecast to retain its lead through 2022, followed by Europe. The North America biotherapeutics cell line development market is fueled by rising prevalence of diseases, strong research and development activities, and rising proportion of geriatric population. Asia Pacific is projected to develop at the fastest pace from 2015 to 2022, driven by growing investments by multinational biopharmaceutical manufacturers.
By process, the biotherapeutics cell line development market is bifurcated into single cell cloning and transfection and selection. The segment of single cell cloning is further segmented into FACS, manual limited dilution cloning, ClonePix, and others. Analysts at TMR reveal that accounting for a share of 37.40% in 2014, ClonePix emerged as the leader in the overall market. By cell line development option, the market is divided into outsource, in-house, do-it-yourself (DIY), and hybrid. The rising trend of outsourcing is likely to propel the outsource segment to develop at the fastest pace.
Some of the leading companies operating in the biotherapeutics cell line development market are Catalent Inc., Thermo Fisher Scientific Inc., Sigma-Aldrich Co. LLC., ProBioGen AG, EMD Millipore, Boehringer Ingelheim Group, Beckman Coulter, Selexis SA, Beckton Dickinson & Company, CMC Biologics A/S, Sony Biotechnology Inc., Partec (Sysmex Corporation), and Lonza Group Ltd.
No comments:
Post a Comment